## SEC Form 4

Instruction 1(b).

 $\Box$ 

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

below)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person Form filed by More than One Reporting

STATEMEN	OMB Number Estimated ave			
Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940		hours per resp	oonse: 0.5
<u>LC</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Aldeyra Therapeutics, Inc.</u> [ ALDX ]	5. Relationship of Re (Check all applicable Director		on(s) to Issuer 10% Owner
		Officer (aiv	e title	Other (specify

below)

I

2. Issuer Name and Ticker o 1. Name and Address of Reporting Person\* Aldeyra Therapeuti PERCEPTIVE ADVISORS LLC 3. Date of Earliest Transaction (Month/Day/Year) 01/07/2021 (First) (Middle) (Last) **51 ASTOR PLACE, 10TH FLOOR** 4. If Amendment, Date of Original Filed (Month/Day/Year) ot)

		Table I - Non-Deriva	tive Securities Acquired, Disposed of, or Benef	icially	Owned
(City)	(State)	(Zip)			T CISON
NEW YORK	NY	10003		X	Form file Form file Person

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Common Stock	01/07/2021		Р		500,000	A	<b>\$8.13</b> <sup>(1)</sup>	6,785,458	Ι	See Footnote <sup>(4)</sup>
Common Stock	01/08/2021		Р		347,332	A	<b>\$9.21</b> <sup>(2)</sup>	7,132,790	Ι	See Footnote <sup>(4)</sup>
Common Stock	01/08/2021		Р		152,668	A	\$10.21 <sup>(3)</sup>	7,285,458	I	See Footnote <sup>(4)</sup>
Common Stock	01/08/2021		Р		50,000	A	\$7.6	7,335,458	Ι	See Footnote <sup>(4)</sup>

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) o Dispo of (D	r osed ) r. 3, 4	6. Date Exerc Expiration D (Month/Day/)	ate	7. Titl Amou Secu Unde Deriv Secu 3 and	unt of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

1. Name and Address of Reporting Person $^{*}$							
PERCEPTIVE ADVISORS LLC							
(Last)	(First)	(Middle)					

51 ASTOR PLACE, 10TH FLOOR						
(Street)						
NEW YORK	NY	10003				
(City)	(State)	(Zip)				
1. Name and Address of Reporting Person*						
PERCEPTIVE LIFE SCIENCES MASTER						

## FUND LTD

(Last) 51 ASTOR PLA	(First) CE, 10TH FLOOR	(Middle)		
(Street) NEW YORK	NY	10003		
(City)	(State)	(Zip)		

1. Name and Address of Reporting Person <sup>*</sup> EDELMAN JOSEPH							
(Last) 51 ASTOR PLAC	(First) CE, 10TH FLOOR	(Middle)					
(Street) NEW YORK	NY	10003					
(City)	(State)	(Zip)					

## Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.49 to \$8.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$8.63 to \$9.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.63 to \$10.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its 01/11/2021 investment manager, By: Joseph Edelman, its managing <u>member</u> /s/ Joseph Edelman - for Perceptive Advisors LLC, By: 01/11/2021 Joseph Edelman, its managing member <u>/s/ Joseph Edelman</u> 01/11/2021 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.